Aquestive Therapeutics Inc.
AQST | NASDAQ
$4.78
+$0.17 (+3.69%)
At close: Sep 21, 2026, 4:00 PM ET
$4.74
-$0.04 (-0.84%)
After-hours:
Sep 21, 2026, 7:59 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 44.55M | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M |
Cost of Revenue | 17.15M | 17.87M | 20.83M | 19.39M | 14.99M | 12.96M |
Gross Profit | 27.39M | 39.69M | 29.75M | 28.29M | 35.84M | 32.89M |
Operating Income | -69.65M | -30.77M | -15.1M | -42.07M | -34.68M | -42.89M |
Interest Income | n/a | 3.44M | 16.32M | 99K | 423K | 132K |
Pretax Income | -83.78M | -44.15M | -7.63M | -54.41M | -70.54M | -55.78M |
Net Income | -83.78M | -44.14M | -7.87M | -54.41M | -70.54M | -55.78M |
Selling & General & Admin | 79.85M | 50.18M | 31.75M | 52.88M | 53.48M | 55.89M |
Research & Development | 17.19M | 20.28M | 13.1M | 17.48M | 17.05M | 19.89M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 97.04M | 70.46M | 44.85M | 70.36M | 70.52M | 75.78M |
Interest Expense | 17.1M | 16.82M | 7.46M | 12.44M | 22.46M | 13.02M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 114.2M | 88.33M | 65.69M | 89.75M | 85.51M | 88.74M |
Income Tax Expense | n/a | -14K | 245K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 121.97M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M |
Shares Outstanding (Diluted) | 121.97M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M |
EPS (Basic) | -0.76 | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 |
EPS (Diluted) | -0.76 | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 |
EBITDA | -66.13M | -26.62M | 1.18M | -39.58M | -45.11M | -39.15M |
EBIT | -66.68M | -27.33M | -163K | -41.97M | -48.08M | -42.76M |
Depreciation & Amortization | 559K | 718K | 1.35M | 2.39M | 2.96M | 3.61M |
Add to Watchlist
Select watchlists to add or remove AQST